11 results about "Btk inhibitors" patented technology

The application relates to a preparation method of a BTK inhibitor intermediate. In particular, the application relates to a preparation method of a compound as shown in formula (A'K), which comprises the following steps: a step of preparing a compound as shown in formula (IIK) from a compound as shown in formula (IIIK), and a step of preparing a compound as shown in formula (A'K) from a compound as shown in formula (IIK). The method has high yield and mild reaction conditions, and is suitable for industrial production.

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and / or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

Provided herein are methods of treating cancer using a combination of a compound provided herein (e.g., Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, or Compound 7, or a stereoisomer or mixture of stereoisomers, a pharmaceutically acceptable salt, a tautomer, a prodrug, a solvate, a hydrate, a co-crystal, a clathrate, or a polymorph thereof) and a second active agent. The second active agent is one or more of a PLK1 inhibitor, a BRD4 inhibitor, a BET inhibitor, a NEK2 inhibitor, a AURKB inhibitor, a MEK inhibitor, a PHF19 inhibitor, a BTK inhibitor, a mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BIRC5 inhibitor, or a DNA methyltransferase inhibitor.

Disclosed herein are methods of treating a disease selected from graft-versus-host disease (GVHD), systemic sclerosis (scleroderma), chronic lung allograft dysfunction (CLAD), restrictive allograft syndrome (RAS), and bronchiolitis obliterans syndrome (BOS) using a combination of a BTK inhibitor (such as rilzabrutinib) and belumosudil.

The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer comprising an EZH2 inhibitor and a BTK inhibitor, and it has been confirmed that the therapeutic effect is significantly superior not only in Ebstein-Barr virus (EBV)-associated lymphoma, which has had low therapeutic efficacy until now, but also in other types of cancer.

Disclosed are formulations / compositions comprising a BTK inhibitor, in particular ibrutinib (Formula I) (I) along with methods for making such formulations / compositions, and methods of treatment of diseases or conditions comprising the use of such formulations / compositions.

This invention provides a method for preparing an intermediate for preparing an NTK inhibitor. [Solution] a) Form a reaction mixture comprising the following compound 170, the following compound 181, a palladium catalyst, and a solvent system containing a base, wherein the equivalent ratio of the palladium catalyst to compound 170 is less than approximately 0.001:1 to 0.005:1, (b) The following scheme: TIFF2026086461000160.tif47170 A method is provided which involves reacting a reaction mixture according to the method to form a reaction product mixture containing compound 190.

The present invention relates to a solid form of 1-(4-{[6-amino-5-(4-phenoxyphenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, useful as BTK inhibitors.